The Potential Dangers of Treating Chronic Lyme Disease
Chronic Lyme disease is sometimes a catchall diagnosis for patients with a wide spectrum of musculoskeletal and neuropsychiatric symptoms, fatigue, and generalized pain. And that, in turn, has led to a variety of treatments: courses of antibiotics lasting for months to years, intravenous (IV) infusions of hydrogen peroxide, immunoglobulin therapy, and even stem cell transplants. Those treatments, though, may not lead to substantial long-term improvementin fact, they can be downright harmful.
Clinicians, health departments, and patients have all contacted the Centers for Disease Control and Prevention with reports of life-threatening complications resulting from treatment for chronic Lyme disease, including metastatic bacterial infections, septic shock, Clostridium difficile colitis, and abscesses. Morbidity and Mortality Weekly Report (MMWR) describes five cases that highlight the severity and scope of adverse effects caused by the use of unproven treatments for chronic Lyme disease.
One patient with fatigue and joint pain, for instance, was diagnosed with chronic Lyme disease, babesiosis, and Bartonella infection. When her symptoms worsened despite multiple courses of oral antibiotics, she was switched to IV ceftriaxone and cefotaxime. However, the pain did not lessen; she became hypotensive and tachycardic, and was placed in intensive care. Her condition continued to worsen, and she died. Her death was attributed to septic shock related to central venous catheter-associated bacteremia.
In another case, a woman was first diagnosed with amyotrophic lateral sclerosis (ALS), then, as a second opinion, with chronic Lyme disease. After seven months of intensive antimicrobial treatment, the pain improved, but she got weaker. She also developed intractable C. difficile infection that required prolonged treatment. However, she died of complications of ALSan example, the researchers say, of a missed opportunity for appropriate treatment due to misdiagnosis.
Antibiotics and immunoglobulin therapies are effective and necessary treatments for many conditions, MMWR emphasizeshowever, unnecessary antibiotic and immunoglobulin use provides no benefit to patients while putting them at risk for adverse events.
Source: MMWR, June 2017
Current treatments for Parkinsons disease are only effective in improving motor deficits, but the loss of cognitive abilities is just as devastating. Approximately 25% of patients also experience cognitive deficits that impair function. One problem in developing treatments, however, is that patients with cognitive effects vary widely. Being able to predict the chance that someone with Parkinsons will develop cognitive deficits could be a useful tool, researchers from Brigham and Womens Hospital say. And they think they might have created just the thing: a computer-based risk calculator.
The researchers combined data from 3,200 patients with Parkinsons disease, representing more than 25,000 individual clinical assessments. They evaluated seven known clinical and genetic risk factors associated with developing dementia, and then used the information to build the risk calculator.
By allowing clinical researchers to identify and select only patients at high risk for developing dementia, this tool could help in the design of smarter trials that require a manageable number of participating patients, says Clemens Scherzer, MD, the lead investigator.
By improving clinical trial design, the risk calculator could help in the discovery of new treatments, the researchers say, and then help determine which patients would most benefit from those treatments.
Source: National Institutes of Health, June 2017
Some patients with acute myeloid leukemia (AML) may have trouble with immunotherapy after chemotherapy, researchers say, and they think theyve found one reason why.
The team wanted to perform a deep assessment of the state of the adaptive immune system in AML patients in remission after chemotherapy. They used the response to seasonal influenza vaccination as a surrogate for the robustness of the immune system. They say their approach was unique in that they established a comprehensive picture of the adaptive immunome by simultaneously examining the genetic, phenotypic, and functional consequences of chemotherapy.
Their assessment revealed a dramatic impact in the B-cell compartment, which appeared slower to recover than the T-cell compartment. Of 10 patients in the study, only two generated protective titers in response to vaccination. Most had abnormal frequencies of transitional and memory B cells. The researchers say the inability of AML patients to produce protective antibody titers in response to influenza vaccination is likely due to multiple B-cell abnormalities. They found similar patterns across all of the patients. When they ranked patients based on time elapsed since chemotherapy, the degree of dysfunction was lesser in patients who were farther away from chemotherapy.
The consistent finding of a reduction of memory B cells in all the AML patients suggests that humoral immunity reconstitution is a very long process. The researchers say that a better understanding of the changes in adaptive immune cell subsets after chemotherapy will be useful in designing immunotherapies that can work with existing immune capacity.
Source: Journal of Translational Medicine, July 2017
Investigation by the Centers for Disease Control and Prevention (CDC) of 27 outbreaks of Legionnaires disease between 2000 and 2014 found health-careassociated Legionnaires disease accounted for 33% of the outbreaks, 57% of outbreak-associated cases, and 85% of outbreakassociated deaths. Nearly all were attributed to water system exposures that could have been prevented by effective water management programs.
CDC researchers analyzed 2015 surveillance data from 20 states and the New York City metropolitan area that reported more than 90% of confirmed legionellosis cases to the Supplemental Legionnaires Disease Surveillance System. Of 2,809 cases, 553 were health-careassociated. Definite cases accounted for 3%, and possible cases accounted for 17% of all of the cases reported. Although only a small percentage was definitely related to health care settings, the fatality rate was high at 12%.
Of the 85 definite health-careassociated Legionnaires disease cases, 80% were associated with long-term-care facilities. Of the 468 possible cases, 13% were possibly associated with long-term-care facilities, 49% with hospitals, and 26% with clinics.
The CDC says the number of definite cases and facilities reported is likely an underestimate, in part because of a lack of Legionella-specific testing. Another explanation is that hospital stays are typically shorter than the 10-day period used in the analysis.
One-fourth of patients with definite health-careassociated Legionnaires disease die. Health care providers play a critical role in prevention and response, the CDC says, by rapidly identifying and reporting cases. Legionnaires disease is clinically indistinguishable from other causes of pneumonia, the researchers note. The preferred diagnostic method is to concurrently obtain a lower respiratory sputum sample for culture on selective media and a Legionella urinary antigen test.
In health care facilities, the researchers say, prevention of the first case of Legionnaires disease is the ultimate goal. The best way to do that, they advise, is to have an effective water management program.
Source: Morbidity and Mortality Weekly Report, June 2017
Metabolic syndrome (MetS) is common among patients with coronary artery disease (CAD) and highly prevalent in those with acute ST-elevation myocardial infarction (STEMI). But are all elements of MetS equally good predictors of clinical severity and prognosis?
To find out, researchers from Sestre Milosrdnice University Hospital Center in Zagreb, Croatia, prospectively analyzed data from 250 patients with acute STEMI treated with primary percutaneous coronary intervention. MetS was defined according to the revised National Cholesterol Education ProgramAdult Treatment Panel III (NCEPATP III) and International Diabetes Federation (IDF) criteria. Of the 250 patients, 231 survived for inclusion in the 12-month follow-up.
Patients with and without MetS were analyzed according to obesity indices: body mass index (BMI), central-body adiposity index (BAI), conicity index (Cindex), visceral adiposity index (VAI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR).
Patients with acute STEMI had high rates of central obesity, increased VAI, WHtR, and very high BAI, dyslipidemia, and hypertension. However, they had lower rates of overall obesity and hyperglycemia.
The NCEPATP III and several other obesity indices were superior to overall obesity (BMI) in predicting acute STEMI severityclinical presentation, in-hospital complications, and severity of CAD. WC and MetS as defined by IDF criteria had no influence on it. Moreover, MetS as defined by NCEP-ATP III or IDF and obesity indices had no influence on prognosis of major adverse cardiovascular events (MACE).
Cindex greater than 1.25/1.18, very high BAI, and WHtR of 63/58 or greater increased the risk of total in-hospital complications, dyspnea, and heart failure, respectively. The number of significantly stenosed coronary arteries increased the risk of total MACE. WHR independently increased the risk of significant stenosis of coronary segment 1 and proximal/middle coronary artery segments.
Source: Archives of Medical Science, June 2017
A handheld detector that offers noninvasive real-time imaging can help dermatologic surgeons get a better idea of skin cancer dimensions before committing to surgery, according to a recent study.
Current imaging technologies can lead to excessive or incomplete removal of the cancer, the researchers say. However, multispectral optoacoustic tomography (MSOT) allows the user to differentiate tissue chromophoresthe part of the molecule responsible for its colorand exogenous contrast agents based on their spectral signatures.
The researchers performed MSOT imaging with handheld scanners on 21 patients with nonmelanoma skin cancers. All of the lesions had recognizable images on the MSOT devices, visualizing the shape and thickness of the lesions and providing images with well-resolved tissue chromophores.
Aggressive types of skin cancers can involve deeper structures, the researchers noteanother reason the MSOT detector could be useful. In one case, the depth of the basal cell carcinoma, which included its underlying vasculature, reached beyond 3 mm, which might have gone undetected by other imaging modalities, they say.
Source: Photoacoustics, June 2017
Originally posted here:
Research Briefs September 2017 - P&T Community
- Exosomes Are Being Hyped as a Silver Bullet Therapy. Scientists Say No. - Singularity Hub - December 28th, 2024
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020